ANIK trades 3.1% below Wall Street's consensus target of $21.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ANIK achieves its forward estimates and maintains a stable P/E multiple of 38.4x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Anika Therapeutics, Inc. (ANIK) has a Wall Street consensus price target of $21.00, based on estimates from 7 covering analysts. With the stock currently trading at $20.38, this represents a potential upside of +3.1%. The company has a market capitalization of $273M.
Analyst price targets range from a low of $21.00 to a high of $21.00, representing a 0% spread in expectations. The median target of $21.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ANIK trades at a trailing P/E of -26.8x and forward P/E of 38.4x. Analysts expect EPS to grow +288.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MDXGMiMedx Group, Inc. | $695M | $4.77 | $7.67 | +60.8% | Buy | — | 15 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 OSUROraSure Technologies, Inc. | $275M | $3.99 | $4.00 | +0.3% | Hold | — | 13 |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 LNTHLantheus Holdings, Inc. | $6.5B | $99.97 | $104.48 | +4.5% | Buy | 18.5x | 19 |
 HALOHalozyme Therapeutics, Inc. | $13.3B | $112.44 | $103.00 | -8.4% | Buy | 13.4x | 27 |
 ALGNAlign Technology, Inc. | $10.6B | $148.17 | $205.25 | +38.5% | Buy | 13.1x | 33 |
 GMEDGlobus Medical, Inc. | $10.0B | $73.96 | $98.88 | +33.7% | Buy | 14.8x | 36 |
 PRGOPerrigo Company plc | $1.9B | $13.84 | $36.20 | +161.6% | Hold | 6.2x | 36 |
 OFIXOrthofix Medical Inc. | $371M | $9.18 | $13.40 | +46.0% | Hold | — | 17 |
Quick answers to the most common questions about buying ANIK stock.
The consensus price target for ANIK is $21, close to the current price of $20.375 (3.1% implied move). Based on 7 analyst estimates, the stock appears fairly valued near current levels.
ANIK has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $21 implies 3.1% upside from current levels.
At a forward P/E of 38.4434x, ANIK trades at a premium valuation. The consensus price target of $21 (3.1% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $21 for ANIK, while the most conservative target is $21. The consensus of $21 represents the median expectation. These targets typically reflect 12-month expectations.
ANIK is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ANIK stock forecast based on 7 Wall Street analysts shows a consensus price target of $21, with estimates ranging from $21 (bear case) to $21 (bull case). The median consensus rating is "Buy".
ANIK trades at a forward P/E ratio of 38.4x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
ANIK appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $21 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ANIK analyst price targets range from $21 to $21, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.